Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00309179 · ClinicalTrials.gov registry record · Phase 2
A Phase II Study of the Safety and Efficacy of E7820 Plus Cetuximab in Colorectal Cancer, Preceded by a Run-in Study in Advanced Solid Tumors
A Phase 2 study, sponsored by Eisai.
- Completed
- Registry status
- Phase 2
- Development phase
- 41
- Enrollment target
NCT00309179 is a Phase 2 study that has completed, run by Eisai. The registered enrollment target is 41 participants.
The verdict
NCT00309179, a Phase 2 study, has completed, sponsored by Eisai.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 41 participants
- Enrollment target
Study Summary
This study proposes to determine the safety of the administration of E7820 plus cetuximab and explore the MTD of the combination in a Phase Ib study. In addition, the efficacy of this combination will be explored in patients with colorectal cancer in the Phase II proof of concept phase of the study.
Interventions
- DRUG E7820 plus cetuximab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2007-09-24 |
| Est. Completion | 2017-02-13 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00309179
The ClinicalTrials.gov registry entry for NCT00309179 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eisai, which has 287 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which E7820 plus cetuximab is the first listed.
NCT00309179 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00309179 about?
NCT00309179 is a clinical study titled "A Phase II Study of the Safety and Efficacy of E7820 Plus Cetuximab in Colorectal Cancer, Preceded by a Run-in Study in Advanced Solid Tumors". This study proposes to determine the safety of the administration of E7820 plus cetuximab and explore the MTD of the combination in a Phase Ib study. In addition, the efficacy of this combination will be explored in patients with colorectal cancer in the Phase II proof of concept phase of the study.
What is the current status of trial NCT00309179?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 41 participants. The study started on 2007-09-24. Estimated completion is 2017-02-13.
What interventions are being tested in trial NCT00309179?
The interventions under investigation include: E7820 plus cetuximab (DRUG).
Who is sponsoring clinical trial NCT00309179?
This trial is sponsored by Eisai, which has 287 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.